|
Thyroid Nodule
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF prevalence among thyroid nodules with FNA read as SFM according to the most popular classification systems (i.e., Bethesda V, Thy4, TIR4 category) was searched.The random-effects model was used.
|
31811566 |
2020 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ROC of the subject was constructed to evaluate the diagnostic value of these 2 methods and their combination.BRAF mutation in FNAC of thyroid nodules occurred in 2796 samples (57.35%).
|
31305422 |
2019 |
|
Thyroid Nodule
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to determine the protein expression of BRAF, RAS, RET, insulin like growth factor 1(IGF1), Galectine 3, CD56 in patients with PTC related acromegaly and to compare the extensity of these expressions with normal PTC patients and benign thyroid nodules.
|
29890543 |
2019 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the diagnostic value of the BRAF mutation in cytologically indeterminate thyroid nodules after the reclassification of a variant thyroid carcinoma.
|
30863114 |
2019 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation analysis by ARMS-PCR refines thyroid nodule management.
|
31441082 |
2019 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to estimate the diagnostic value of BRAF V600E mutation status combined with cytomorphological features for diagnosis of papillary thyroid cancer (PTC) in cytologically indeterminate thyroid nodules.
|
29566402 |
2019 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter and BRAF mutations were detected in 20/436 (4.6%) and 257/434 thyroid nodules (59.2%), respectively.
|
31042674 |
2019 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Utility of including BRAF mutation analysis with ultrasonographic and cytological diagnoses in ultrasonography-guided fine-needle aspiration of thyroid nodules.
|
30118506 |
2018 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
False-negative rate of BRAF mutation testing with FNAC for thyroid nodules is increased in cases of old age, indeterminate FNAC pathology results, and certain PTC subtypes.
|
29132392 |
2017 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Critical Pitfalls in the use of BRAF Mutation as a Diagnostic Tool in Thyroid Nodules: a Case Report.
|
26782803 |
2016 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules.
|
26215382 |
2016 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whether preoperative knowledge of the BRAF mutation status would help to determine the extent of surgery for thyroid nodules is still under investigation.
|
26854757 |
2016 |
|
Thyroid Nodule
|
0.100 |
Biomarker
|
disease |
BEFREE |
To date, there is no high-level evidence supporting or refuting a role for BRAF analysis in thyroid nodules with prior indeterminate cytology.
|
25920006 |
2016 |
|
Thyroid Nodule
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
|
26749005 |
2016 |
|
Thyroid Nodule
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We conducted a pilot study on the diagnosis of thyroid nodules by analysis of promoter hypermethylation status with reference to BRAF(V) (600E) mutation and cytopathology results using formalin-fixed, paraffin-embedded (FFPE) tissues and liquid-based preparation (LBP) thyroid fine needle aspiration (FNA) samples to predict more reliably the possibility of papillary carcinoma.
|
25988212 |
2016 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Coexisting mutations overall were not identified in BRAF(K601E) mutated thyroid nodules except in a case that exhibited a complex K601E + T599I mutation and had a classic PTC phenotype.
|
26422023 |
2016 |
|
Thyroid Nodule
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the 65 BRAF(V) (600E) -negative indeterminate thyroid nodules identified by FNAC, 25 (38·5%) exhibited point mutations in RAS 61 consisting of 18 NRAS 61 (72%), and 7 HRAS 61 (28%) mutations.
|
25109485 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutational analysis followed by N, H, and KRAS codon 61 mutational analysis in indeterminate thyroid nodules would streamline the management of patients with malignancies, mostly FVPTC.
|
25648502 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to determine BRAF T1799A mutation and KRas proto-oncogene mutation, and the analysis of RASSF1A promoter methylation level in cytological material obtained from FNAB specimens of thyroid nodules.
|
26457492 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to evaluate the diagnostic utility of BRAF mutation testing on thyroid nodules "suspicious for papillary thyroid carcinoma" (PTC) cytology.
|
24989827 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the clinical, US features, and outcome of patients with thyroid nodules with benign cytology but positive BRAF(V600E) mutation using highly sensitive analytic methods from US-FNA.
|
25616949 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified studies reporting BRAF(V600E) mutation analysis after FNA for evaluation of thyroid nodules through searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, scanning reference lists of relevant studies, and contacting experts.
|
26232865 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of the Anyplex BRAF V600E real-time detection assay using dual-priming oligonucleotide technology in fine-needle aspirates of thyroid nodules.
|
26354351 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RAS mutation has limited value in predicting malignancy among BRAF mutation-negative thyroid nodules with AUS/FLUS cytology and further, investigation is anticipated to evaluate the true role of RAS mutation in thyroid malignancy.
|
26166089 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.
|
26597052 |
2015 |